Since this year, more than 30 innovative oncology drugs have been approved in China. Targeted drugs have continued to fill previously difficult targets such as KRAS G12C, EGFR 20ins, NTRK, FGFR, and MET, and the accessibility of targeted therapy has continued to improve. At the same time, the cancer vaccine circuit is speeding up at the same time. The industry believes that targeted drug target verification is mature and has entered the stage of commercialization and homogenization competition; cancer vaccines are still in the cutting-edge exploration and clinical verification stage. The industry is optimistic about the collaboration between the two: while targeted drugs shrink tumors, cancer vaccines use active immunization mechanisms and combined medication to improve treatment effectiveness. However, there is still great uncertainty about whether a large number of vaccine pipelines can successfully pass phase II/III clinical verification.

Since this year, more than 30 innovative oncology drugs have been approved in China. Targeted drugs have continued to fill previously difficult targets such as KRAS G12C, EGFR 20ins, NTRK, FGFR, and MET, and the accessibility of targeted therapy has continued to improve. At the same time, the cancer vaccine circuit is speeding up at the same time. The industry believes that targeted drug target verification is mature and has entered the stage of commercialization and homogenization competition; cancer vaccines are still in the cutting-edge exploration and clinical verification stage. The industry is optimistic about the collaboration between the two: while targeted drugs shrink tumors, cancer vaccines use active immunization mechanisms and combined medication to improve treatment effectiveness. However, there is still great uncertainty about whether a large number of vaccine pipelines can successfully pass phase II/III clinical verification.